Cost-effectiveness of pembrolizumab plus chemotherapy as first line treatment in PD-L1-positive metastatic TNBC. Supplementary Tables.
dataset
posted on 2022-07-07, 07:52 authored by Joyce O'Shaughnessy, Nicolas Cappoen, Celine Le Bailly De Tilleghem, Zheng-Yi Zhou, Emma Gray, Wilbur James. Pan, Amin Haiderali, Peter Fasching, Min Huang, Mitashri Chaudhuri<p> </p>
<p><strong>Supplementary Table S1. </strong>AIC/BIC of parametric function fitting for OS, PFS and ToT</p>
<p><br></p>
<p> </p>
<p><strong>Supplementary Table S2.</strong> AE related hospitalization costs (2021 USD)</p>
<p><br></p>
<p> </p>
<p><strong>Supplementary Table S3.</strong> Summary of scenario analyses results</p>
<p><br></p>
<p> </p>
<p><strong>Supplementary Table S4.</strong> Summary of subgroup analysis results</p>
<p><br></p>
<p> </p>
<p><strong>Supplementary Table S5.</strong> Cost-effectiveness results for pembrolizumab plus chemotherapy (weighted average) vs. chemotherapy (weighted average)</p>
